Share chart Aurinia Pharmaceuticals Inc.
Extended chart
Simple chart
About Aurinia Pharmaceuticals Inc.
Биофармацевтическая компания Aurinia Pharmaceuticals Inc. разрабатывает и коммерциализирует методы лечения различных заболеваний, при которых медицинские потребности не удовлетворяются в Японии и Китае. Компания предлагает ЛУПКИНИС для лечения взрослых пациентов с активным волчаночным нефритом. У нее есть соглашение о сотрудничестве и лицензионное соглашение с Otsuka Pharmaceutical Co., Ltd. Штаб-квартира компании находится в Виктории, Канада.| IPO date | 1999-01-26 |
|---|---|
| ISIN | CA05156V1022 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | https://www.auriniapharma.com |
| Цена ао | 8.15 |
| Change price per day: | -0.4908% (8.15) |
|---|---|
| Change price per week: | -0.4908% (8.15) |
| Change price per month: | +3.84% (7.81) |
| Change price per 3 month: | -13.45% (9.37) |
| Change price per half year: | +13.74% (7.13) |
| Change price per year: | +56.87% (5.17) |
| Change price per 3 year: | -34.54% (12.39) |
| Change price per 5 year: | -32.98% (12.1) |
| Change price per 10 year: | 0% (8.11) |
| Change price per year to date: | -10.19% (9.03) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Armistice Capital, LLC | 12 | 8.59 |
| Blackrock Inc. | 9 | 6.07 |
| NEA Management Company, LLC | 4 | 2.78 |
| State Street Corporation | 3 | 1.94 |
| Goldman Sachs Group Inc | 2 | 1.51 |
| Nuveen Asset Management, LLC | 2 | 1.44 |
| Tang Capital Management, LLC | 2 | 1.44 |
| Geode Capital Management, LLC | 2 | 1.12 |
| Vanguard Group Inc | 2 | 1.07 |
| Morgan Stanley | 1 | 0.91 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Future Tech ETF | 0.10135 | 426.34 | 0.8416 |
| Principal Healthcare Innovators ETF | 0.10135 | 618.5 | 0.8416 |
iShares Russell 2000 Growth ETF
|
0.05241 | 38.04 | 0.6026 |
| iShares Morningstar Small-Cap Growth ETF | 0.02593 | 33.63 | 0.72598 |
| iShares Morningstar Small-Cap Growth ETF | 0.02593 | 587.89 | 0.72598 |
| iShares Morningstar Small-Cap ETF | 0.02128 | 391.25 | 1.60498 |
| iShares Morningstar Small-Cap ETF | 0.02128 | 30.1 | 1.60498 |
| iShares Morningstar Small Cap Value ETF | 0.01584 | 26.7 | 2.50476 |
| iShares Morningstar Small-Cap Value ETF | 0.01584 | 201.65 | 2.50476 |
| iShares Russell 3000 ETF | 0.00184 | 24.83 | 1.43482 |
| 0.04 | 237.89 | 1.34 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Peter S. Greenleaf M.B.A. | President, CEO & Director | 1.34M | 1970 (55 years) |
| Mr. Matthew Maxwell Donley M.B.A. | Executive Vice President of Operations & Strategy | 811.82k | 1969 (56 years) |
| Mr. Stephen P. Robertson | Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer | 739.68k | 1982 (43 years) |
| Mr. Michael R. Martin | Chief Business Officer | 350.57k | 1972 (53 years) |
| Mr. Joseph M. Miller CPA | Chief Financial Officer | 791.92k | 1974 (51 year) |
| Ms. Sue Evans | Senior Vice President of Global Regulatory Affairs | N/A | |
| Mr. Scott Habig | Chief Commercial Officer | N/A | 1960 (65 years) |
| Ms. Andrea Levin Christopher | Head of the Corporate Communications & Investor Relations | ||
| Dr. Gregory F. Keenan M.D. | Chief Medical Officer | ||
| Dr. Ann M. Daus Ph.D. | Senior Vice President of Quality |
Address: Canada, Victoria, BC VZ X, 4464 Markham Street - open in Google maps, open in Yandex maps
Website: https://www.auriniapharma.com
Website: https://www.auriniapharma.com
